Tazilsun Indications/Uses

Piperacillin/tazobactam is indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: Lower respiratory tract infections; Urinary tract infections (complicated and uncomplicated); Intra-abdominal infections; Skin and skin structure infections; Bacterial septicaemia; Gynaecological infections; Bacterial infections in neutropenic patients in combination with an aminoglycoside; Bone and joint infections.
Polymicrobic infections: Piperacillin/tazobactam is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological).
While piperacillin/tazobactam is indicated only for the conditions listed previously, infections caused by piperacillin susceptible organisms are also amenable to piperacillin/tazobactam treatment due to its piperacillin content. Therefore, the treatment of mixed infections caused by piperacillin susceptible organisms and β-lactamase producing organisms susceptible to piperacillin/tazobactam should not require the addition of another antibiotic.
Appropriate culture and susceptibility tests should be performed before treatment in order to identify organisms causing infections and to determine their susceptibilities to piperacillin/tazobactam. Because of its broad-spectrum of activity against Gram-positive and Gram-negative aerobic and anaerobic organisms as listed previously, piperacillin/tazobactam is particularly useful in the treatment of mixed infections and in presumptive therapy prior to the availability of the results of susceptibility tests. Therapy with piperacillin/tazobactam may, however, be initiated before results of such tests are known. Modification of the treatment may be required once these results become available or if there is no clinical response.
In serious infections, presumptive therapy with piperacillin/tazobactam may be initiated before susceptibility test results are available.
Piperacillin/tazobactam acts synergistically with aminoglycosides against certain strains of Pseudomonas aeruginosa. Combined therapy has been successful, especially in patients with impaired host defences. Both drugs should be used in full therapeutic doses. As soon as results of culture and susceptibility tests become available, antimicrobial therapy should be adjusted.
In the treatment of bacterial infections in neutropenic patients, full therapeutic doses of piperacillin/tazobactam plus an aminoglycoside should be used. Periodical electrolyte determinations should be made in patients with low potassium reserves and the possibility of hypokalaemia should be kept in mind with patients who have potentially low potassium reserves.